# Januvia Re-examination Study (MK-0431-181)

> **NCT01062048** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 3483 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Sulfonylurea
- **BIOLOGICAL:** Insulin

## Key facts

- **NCT ID:** NCT01062048
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 3483 (ACTUAL)
- **Last updated:** 2016-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01062048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01062048, "Januvia Re-examination Study (MK-0431-181)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01062048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*